微芯生物西格列他钠二甲双胍缓释片临床试验申请获得受理

Core Viewpoint - Microchip Biotech (688321) has received acceptance for its clinical trial application for the combination drug of Siglecatin Sodium and Metformin Hydrochloride for treating adult patients with type 2 diabetes from the National Medical Products Administration [1] Group 1 - The company and its wholly-owned subsidiary Chengdu Microchip Pharmaceutical Co., Ltd. have recently received the acceptance notice for the clinical trial application [1] - The clinical trial application is for a self-developed drug, which is a combination of PPAR full agonist and Metformin [1] - Currently, there are no PPAR full agonist and Metformin combination formulations in clinical trial stages globally [1]